肌少症与失代偿期肝硬化进展及死亡相关,代偿期则不然:多中心研究
结果显示肌少症仅在失代偿期肝硬化中独立关联进展或死亡(aHR 1.43)及单独死亡(aHR 1.55),在代偿期和失代偿期均关联非计划住院。
要点
- 失代偿期肝硬化合并肌少症者进展或死亡风险独立升高(aHR 1.43)。
- 代偿期肝硬化中肌少症未独立关联进展或死亡。
- 肌少症在代偿期和失代偿期均独立关联非计划住院。
核心结论
- 肌少症仅在失代偿期肝硬化中独立关联肝硬化进展或死亡及单独死亡,在代偿期无此独立关联。
研究设计与样本
- 肌少症用腹部CT第3腰椎(L3)骨骼肌指数(SMI)测量,肝硬化进展按D'Amico分类临床分期较基线升高定义。
- 采用单变量和多变量Cox回归模型评估与进展或死亡、单独死亡及住院相关的因素,并分别分析代偿期和失代偿期肝硬化。
主要发现
- 在失代偿期肝硬化中,肌少症独立关联进展或死亡(aHR 1.43,95% CI 1.14-1.79,p=0.002)。
- 在失代偿期肝硬化中,肌少症独立关联单独死亡(aHR 1.55,95% CI 1.19-2.03,p=0.001)。
- 在代偿期肝硬化中,肌少症与进展或死亡及单独死亡无独立关联。
- 肌少症独立关联失代偿期肝硬化的非计划住院(aHR 1.32,95% CI 1.08-1.63,p=0.007)。
临床怎么用
- 对失代偿期肝硬化患者应评估肌少症,以识别进展或死亡风险较高者。
- 对代偿期和失代偿期肝硬化患者,肌少症评估有助于识别非计划住院风险较高者。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcopenia is associated with increased mortality in patients awaiting liver transplant (LT), but the impact of sarcopenia on cirrhosis progression remains under-evaluated. AIMS: We aimed to explore the relationship between sarcopenia and the risk of cirrhosis progression, mortality and hospitalisation in compensated and decompensated cirrhosis. METHODS: Sarcopenia was measured using the skeletal muscle index (SMI) obtained from abdominal CT imaging at the 3rd lumbar vertebra (L3). Progression of cirrhosis was defined by an increase in clinical stage from baseline using the D'Amico classification. Factors associated with progression or death, death alone and hospitalisation were evaluated with univariate and multivariate Cox regression models. RESULTS: One thousand six hundred and twenty-four adult patients with cirrhosis from five centres across Europe, North America and Asia were included. Mean age was 54 ± 9 years, 26% of patients were female, 31% had compensated disease and mean MELD-Na was 15 ± 7. With separate analyses for compensated and decompensated cirrhosis, sarcopenia was independently associated with the risk of progression or death (aHR 1.43, 95% CI 1.14-1.79, p = 0.002) and death alone (aHR 1.55, 95% CI 1.19-2.03, p = 0.001) only in decompensated cirrhosis. Sarcopenia was independently associated with unplanned hospitalisation in both compensated (aHR 1.70, 95% CI 1-15-2.51, p = 0.010) and decompensated cirrhosis (aHR 1.32, 95% CI 1.08-1.63, p = 0.007). CONCLUSIONS: Sarcopenia was independently associated with cirrhosis progression or death and death alone in decompensated cirrhosis. Future studies are needed to evaluate the possibility of slowing cirrhosis disease progression by reversing or preventing sarcopenia.
引用
- Tandon P, Wang S, Kim MY, et al. Sarcopenia Is Associated With Mortality and Progression of Cirrhosis in Decompensated but Not Compensated Disease-A Multicentre Study. Aliment Pharmacol Ther. 2026. PMID: 41913062. doi:10.1111/apt.70636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。